National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
Health Canada and European Regulators have approved BENLYSTA™.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA®.
Dario Dieguez, PhD, from the Lupus Foundation of America joined leading NIH lupus experts to explore current issues in lupus, including risk factors and treatment therapies.
Program provides lupus education to nurses, pharmacists, and pharmacy technicians.
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
Human Genome Sciences and GlaxoSmithKline announced publication of the BLISS-52 study of BENLYSTA®.